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ABSTRACT 
 
EMILY ANN NESBIT: EXPLORATION IN THE EFFECTIVENESS OF SOLID LIPID 
NANOPARTICLE FORMULATIONS IN ENHANCING OCULAR DELIVERY OF 
WIN 55, 212 IN THE TREATMENT OF GLAUCOMA  
 
(Under the direction of Dr. Soumyajit Majumdar)  
 
Glaucoma is a progressive and degenerative ocular disease which, without proper 
treatment, can result in permanent blindness. Due to a complex organization of lipophilic 
and hydrophilic ocular membranes, topical delivery of therapeutic agents has also proved 
to be a challenging task. Cannabinoids, such as Δ9-Tetrahydrocannabinol (THC), have 
intraocular pressure (IOP) lowering and neuroprotective capabilities. Due to the 
unfavorable physiochemical characteristics of these molecules, delivery into the eye 
through a topical route is very difficult. Previous research has shown that prodrug 
derivatization and formulations such as solid lipid nanoparticles (SLNs) improve the 
physiochemical characteristics and ocular bioavailability of such molecules. WIN 55, 212 
(WIN) is a synthetic cannabinoid possessing a structure similar to THC and is fifty times 
more potent. WIN 55, 212 (212) also possesses slightly better physiochemical 
characteristics than THC. 
 The goal of this research is to develop solid lipid nanoparticle formulations that 
will enhance the intraocular delivery of WIN 55, 212. The particle size, entrapment 
efficiency, and content of the SLN formulations will be standardized. In vitro and in vivo 
studies will be carried out to determine the benefit of the SLNs over conventional 
formulations. In vitro transcorneal permeability studies will be carried out utilizing a 
Franz diffusion apparatus and corneas dissected from rabbit eyes. Samples will be taken 
at different time intervals throughout the permeability study and analyzed using a HPLC-
UV system. The in vivo IOP lowering evaluation studies will be performed on male New 
Zealand albino rabbits that have artificially induced glaucoma. Fifty microliters of 0.4% 
w/v SLN’s (Dose: 0.2 mg) will be topically applied to the cul-de-sac of each rabbit’s eye. 
An equivalent dose of WIN 55, 212 in Tocrisolve® will be used as the control. The study 
will take place until the IOP returns to 90% of the baseline levels. Following the 
conclusion of the study, the animals will be anesthetized and euthanized with a sufficient 
dose of pentobarbital injected through the marginal ear vein. Immediately, the eyes will 
be enucleated and the ocular tissues will be isolated, weighed, and analyzed for WIN 55, 
212 content. The goal of this project is to increase the retention of WIN 55, 212 in the eye 
and prolong the intraocular lowering duration compared to the control formulation.  
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Background 
 
I. The Pathophysiology and Epidemiology of Glaucoma  
 
 Glaucoma is an ocular disease that stands as the second leading cause of blindness in the 
United States and affects nearly 70 million people worldwide (Shaikh, Yu, & Coleman, 2014). 
Glaucoma is defined as a neuropathic ocular disease, characterized by the disruption of normal 
functions of the peripheral nerves within the eye (Cook & Foster, 2012). Although the 
pathogenesis of the disease remains poorly understood, an increase in intraocular pressure (IOP) 
within the eye is correlated to an increase in the death of retinal ganglion cells. This cellular 
process results in the most common clinical manifestation of glaucoma: vision loss (Weinreb, 
Aung, & Medeiros, 2014).  
 The retinal ganglion cells are the last in a chain of optic cells which begin with the 
photoreceptors. As pressure rises within the eye, the area where the nerve fibers of the retinal 
ganglion cells pass, known as the lamina cribrosa, compresses and results in thinning of the 
neuroretinal rim. Compression of the lamina cribrosa results in the clinical phenomenon of 
‘cupping’, where the optic cup expands as a result of the decreased thickness of the neuroretinal 
rim (Healey & Thomas, 2010). Continual compression of the neuroretinal rim leads to retinal 
ganglion cell (RGC) death, which is associated with the visual impairments that glaucoma 
patients experience.   
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Cupping in POAG (Janssen et al., 2013)  
Figure 1 
 
I. 1 A Brief Overview of Ocular Anatomy 
 
 To understand the complexities of glaucoma and the treatment options available, a basic 
understanding of the anatomical structure of the eye is necessary. The eye is divided by the lens 
into two fluid-filled sections, the anterior segment which contains the aqueous humor and the 
posterior segment which contains the vitreous humor (Purves, Augustine, Fitzpatrik, Katz, 
LaMantia, McNamara, & Williams, 2001). The visual pathway begins with the cornea, a 
transparent structure that allows light to enter the eye and travel through the pupil, which is 
surrounded by the iris, the colored portion of the eye that expands and contracts depending on 
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the magnitude of light entering the eye (Peate & Jones, 2014). The final structure of the anterior 
segment is the lens, which is supported by the ciliary muscles and serves to refract and focus 
incoming light onto the retina (Peate & Jones, 2014). The aqueous humor encompasses each of 
these structures and is produced by the ciliary body. Inadequate drainage of the aqueous humor 
through the trabecular meshwork is the main culprit in the development of glaucoma (Purves, 
Augustine, Fitzpatrik, Katz, LaMantia, McNamara, & Williams, 2001). The current treatment 
options for glaucoma aim to decrease aqueous humor production or increase the drainage 
through the trabecular meshwork (Weinreb et al., 2014).  
 The space between the back of the lens and the retina, known as the posterior segment, is 
filled with the vitreous humor, a gelatinous substance that comprises approximately 80% of the 
total volume of the eye (Purves et al., 2001). The retina contains the cells involved in the visual 
pathway, beginning with the photoreceptors and ending with the retinal ganglion cells (RGCs). 
The axons of these cells synapse at the optic nerve in the lateral geniculate nucleus located in the 
thalamus (Healey & Thomas, 2010). The anatomy of the eye can be visualized in Figure 2.  
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Anatomy of the eye (National Eye Institute) 
Figure 2 
 
 
I. 2 Different Subtypes of Glaucoma and Their Associated Risk Factors 
 
 The two broad categories of glaucoma are open-angle and angle-closure, and can 
manifest either randomly or be secondary conditions resulting from use of certain medications, 
pre-existing conditions, or trauma. Although both subtypes result in the death of retinal ganglion 
cells, there are distinct differences in how the aqueous humor drains through the trabecular 
meshwork and uveoscleral outflow pathway, which can be seen in Figure 3.  
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Aqueous humor drainage in healthy and glaucomatous eyes (Weinreb et al., 2014)  
Figure 3  
  
 Primary open angle glaucoma (POAG) is the most prevalent form of the disease and 
results from increased resistance of aqueous humor outflow through the trabecular meshwork, a 
drainage pathway located in the anterior chamber of the eye at the junction of the cornea and 
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ciliary body (Janssen et al., 2013). The pathogenesis of this phenomenon is poorly understood, 
and POAG is often described as being insidious due to its slow progression, with many patients 
only receiving a diagnosis after their vision has deteriorated quite significantly (Janssen et al., 
2013). Some of the risk factors associated with the development of POAG include a family 
history of glaucoma, older age, belonging to the African American race, high intraocular 
pressure, and the use of systemic or topical corticosteroids (Weinreb et al., 2014). Research has 
suggested that myopia (nearsightedness), high fasting capillary blood glucose levels, and 
increased levels of high-density lipoprotein cholesterol may also put individuals at risk of 
developing POAG (Kim, Jeoung, & Park, 2014). The role of genetics has also been called into 
question, and although less than 10% of all glaucoma cases can be attributed to a genetic 
predisposition, recent studies have identified certain alleles that may increase a patient’s risk of 
developing the disease (Mabuchi, Sakurda, Kashiwagi, Yamagata, Ijima, & Tsukahara, 2015).   
 The other main categorization of the disease in angle-closure glaucoma, which is 
characterized by the site of aqueous humor outflow being anatomically obstructed by the iris 
(Weinreb et al., 2014). This subtype of glaucoma disproportionately affects people of Chinese, 
Mongolian, and Indian descent and the highest prevalence rates have been found in those 
belonging to the Eskimo and Inuit ethnicities (Tarongoy, Ho, & Walton, 2009). Angle-closure 
glaucoma can either be acute, which is considered a medical emergency, or chronic. The risk 
factors for developing chronic angle-closure glaucoma are more understood than POAG because 
they are primarily morphological in nature. In addition to the increased prevalence seen in Asian 
countries, other risk factors include a shallow anterior chamber, short axial length, thicker lens, 
hyperopia, and belonging to the female sex (Zhang, Wang, Aung, Jonas, & Wang, 2015). 
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I. 3 Diagnosing Glaucoma  
 Older age, a family history of glaucoma, African or Latino ethnicity, diabetes mellitus, 
myopia, and low blood pressure are all easily identifiable risk factors for developing POAG. 
However, specific diagnostic exams are required to identify the physiologic risk factors of high 
IOP levels, disc hemorrhage, a large cup-to-disc ratio, and a high pattern standard deviation on 
threshold visual field testing (McLeod et al., 2016). Proper diagnosis of PAOG begins with 
evaluation the patient’s self-reports of vision, with common complaints being difficulties with 
night driving and reading (McLeod et al. 2016). After evaluating a patient’s history visual acuity 
should be measured, the pupils should be dilated, and the anterior chamber of the eye should be 
examined using a slit-lamp (McLeod et al. 2016). Intraocular pressure in a major consideration 
during diagnosis, and the gold standard is by utilizing the Goldmann tonometry method. An IOP 
exceeding 22 mmHg is considered abnormal, but some studies have found that anywhere from 
25-50% of people diagnosed with glaucoma had IOP readings less than 22 mmHg (Weinreb et 
al., 2014). Although the best way to visualize the effects of glaucoma is to perform visual field 
exams and optic nerve imaging, it is estimated that 30-50% of retinal ganglion cell death occurs 
before abnormalities can be detected during these tests.  
 In addition to assessing risk factors and elevated IOP levels, primary angle-closure 
glaucoma has traditionally been diagnosed using goniscopic imaging, but newly developed 
anterior segment optical coherence tomography imagine (AS-OCT) has proved to be more 
reliable (Weinreb et al., 2104). Optical coherence tomographic imaging allows for precise 
measurement of the angle of aqueous outflow, making it a vital diagnostic tool for PACG in 
ophthalmology.  
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II. Therapeutic Approaches in Managing Glaucoma  
 Following the diagnosis of glaucoma, the main therapeutic goal for the patient is to keep 
their IOP within the normal range of 10-21 mmHg and to prevent further damage to the optic 
nerve (Weinreb et al., 2014). Several large scale randomized controlled trials have shown that 
controlling IOP is the only effective method to control glaucoma progression (Weinreb et al., 
2014). Research into the effectiveness of surgical versus pharmaceutical therapies for glaucoma 
have shown that no significant benefit exists for surgical interventions (Burr, Azuara-Blance, 
Avenell, & Tuulonen, 2012). There are a variety of different therapeutic approaches to treat 
glaucoma, each having their own benefits and adverse effects.  
II. 1 Prostaglandin Analogues – Pharmaceutical Therapies for Glaucoma  
 A study published in 1996 provided evidence that latanoprost, a newly approved 
prostaglandin analogue, showed significant reduction in IOP when compared to timolol, a β-
adrenergic blocker (Camras, 1996). This study, along with evidence provided by additional 
research, quickly made prostaglandin analogues (PGAs) the first-line therapeutics for the 
treatment of glaucoma. Currently there are five FDA-approved PGAs on the market: latanoprost 
travoprost, tafluprost, unoprostone, and bimatoprost (Weinreb et al., 2014). PGAs exert their 
mechanism of action by increasing the outflow of aqueous humor through the uveoscleral 
pathway and have been proven to lower IOP levels by up to 50% (Drug Therapy of Glaucoma, 
2015). If target IOP levels are not being attained with a PGA alone, it is possible to add other 
medications to a patient’s therapeutic regimen. As with any pharmaceutical therapy, adverse 
effects have been reported, but in comparison to other glaucoma treatments PGAs have less 
serious systemic side effects. Some of the common local adverse effects include conjunctival 
hyperemia, lengthening and darkening of the eyelashes, brown discoloration of the iris, uveitis, 
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and macular edema (Weinreb et al., 2014). Interestingly, one of these effects, lengthening of the 
eyelashes, gave rise to the first FDA-approved drug for inadequate eyelashes, Latisse. Studies 
into iris pigmentation changes caused by PGAs have shown that up to 70% of individuals may 
experience this adverse effect, although many changes were subtle (Figure 4). PGAs have few, if 
any, systemic side effects, although some studies suggest that their use may lead to the 
development of headaches (Weinreb et al., 2014).  
 
 
Iris hyperpigmentation due to PGA use versus normal eye (Teus, Arranz-Marquez, & Lucea-
Suescun, 2002) 
Figure 4 
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II. 2 β-Adrenergic Blockers – Pharmaceutical Therapies for Glaucoma 
 
 Prior to the introduction of prostaglandin analogues, β-Adrenergic blockers, commonly 
referred to as beta blockers, were the first-line therapeutics for the treatment of glaucoma 
(Glaucoma, 2015). Currently there are five FDA-approved beta blockers for the management of 
glaucoma: timolol, levobunolol, cartelol, metipranolol, and betaxolol (Weinreb et al., 2014). Beta 
blockers exert their therapeutic effect by decreasing the amount of aqueous humor produced by 
the ciliary body in the eye (Weinreb et al., 2014). Beta blockers typically decrease IOP levels by 
25%, only slightly less than PGAs, but carry with them more serious systemic side effects and 
their use is contraindicated in some patients (Glaucoma, 2015). PGAs exert their action for a full 
24 hours, while beta blockers typically only last 12 hours. In addition, beta blockers must be 
administered by the patient in the morning, a factor thought to decrease patient compliance 
(Glaucoma, 2015).  
 The local adverse effects of beta blockers are minor and include irritation and dry eyes. 
Beta blockers are contraindicated in patients with obstructive respiratory illnesses, and patients 
with even mild cases of COPD can experience serious exacerbations after using these 
therapeutics (Healey & Thomas, 2010). Although beta blockers no longer serve as the first-line 
treatment for glaucoma, their use in combination with other classes of glaucoma drugs, most 
commonly PGAs, have been shown to further reduce IOP levels (Healey & Thomas, 2010). 
Currently there are three combinations of PGAs and beta blockers available to treat glaucoma: 
bimatoprost/timolol, latanoprost/timolol, and travoprost/timolol (Healey & Thomas, 2010).  
II. 3 α-Adrenergic Agonists – Pharmaceutical Therapies for Glaucoma  
 There are currently two FDA-approved α-adrenergic agonists on the market, brimonidine 
and apraclonidine (Weinreb et al., 2014). These therapeutics, commonly referred to as alpha 
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agonists, exert their action both by reducing aqueous humor production and increasing aqueous 
humor outflow (Weinreb et al., 2014). Alpha agonists prove effective at lowering IOP levels, but 
patient adherence is a concern because the medication must be applied topically three times daily 
to achieve maximum results (Healey & Thomas, 2010). Alpha agonists are contraindicated in 
patients taking monoamine oxidase inhibitors and may produce unpleasant side effects including 
drowsiness (Healey & Thomas, 2010). Alpha agonists serve as a good alternative for patients 
experiencing bothersome or allergic reactions from other classes of glaucoma drugs, and they can 
be used in combination with other therapeutics to further lower IOP (Weinreb et al., 2014). There 
are currently two FDA-approved combination drugs containing alpha agonists: Combigan 
(brimonidine/timolol) and Simbrinza (brimonidine/brinzolamide).  
II. 4 Carbonic Anhydrase Inhibitors – Pharmaceutical Therapies for Glaucoma  
 Carbonic anhydrase inhibitors (CAIs) are unique because they can be delivered both 
topically and orally, making them a good option for patients not responding well to topically 
applied eye drops (Healey & Thomas, 2010). There are two topical CAIs, dorzolamide and 
brinzolamide, and an oral CAI, acetazolamide. CAIs, like beta blockers, exert their effects by 
decreasing the amount of aqueous humor produced (Weinreb et al., 2014). Topical administration 
of CAIs results in minimal adverse effects, but oral delivery can result in paresthenia, nausea, 
diarrhea, loss of appetite, and renal stones (Weinreb et al., 2014). This class of drugs are most 
often utilized in combination formulations. The two combination drugs that include CAIs are 
Cosopt (dorzolomide/timolol) and Simbrinza (brinzolamide/brimonidine). Simbrinza does not 
contain a beta blocker, making it an ideal addition for a patient with an obstructive respiratory 
disease that does not respond well to a PGA alone (Glaucoma, 2015).  
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II. 5 Cholinergic Agonists – Pharmaceutical Therapies for Glaucoma  
 Although cholinergic agonists are the least prescribed class of glaucoma medications 
prescribed today, they became the first viable treatment option in 1875 with the discovery of 
pilocarpine (Weinreb et al., 2014). The two cholingeric agonists approved for the management of 
glaucoma, pilocarpine and carbachol, work by increasing aqueous humor outflow by contracting 
the ciliary muscles, resulting in decreased resistance in the trabecular meshwork drainage pathway 
(Weinreb et al., 2014).  
II. 6 Laser Trabeculoplasty – Surgical Approaches to Glaucoma Management 
The laser trabeculoplasty procedure was first performed in 1974 by Worthen and 
Whickham, and became a common surgical option for POAG after the publication of Wise and 
Witter’s pilot study in 1979 (Sayyad & Helal, 2009). This procedure has an excellent safety record 
and is indicated for patients who cannot tolerate topically applied medications or patients who 
cannot undergo more invasive forms of glaucoma surgery, like a trabeculotomy (Dietlein, 
Hermann, & Jordan, 2009). This procedure utilizes the energy of a laser to lower the resistance in 
the trabecular meshwork and induce an increase in aqueous humor outflow (Healey & Thomas, 
2010). Research has shown that this procedure results in a 20% reduction in IOP levels (Dietlein 
et al., 2009).  
II. 7 Trabeculotomy – Surgical Approaches to Glaucoma Management  
A trabeculotomy is the most commonly performed incisional surgical procedure for the 
treatment of glaucoma, and is indicated in patients whose glaucoma has advanced despite the use 
of several topical medications or for patients who are non-compliant to medication regimens 
(Dietlein et al., 2009). A large scale randomized controlled trial showed that IOP levels were 
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significantly lower in surgically treated patients when compared to those using topically 
administered glaucoma medications (Musch, Gillespie, Palmberg, Spaeth, Niziol, & Lichter, 
2014). The downside of a trabeculotomy is the possibility of excessive scarring, which results in 
failure of the procedure, but antifibrotic agents including mitomycin-C and 5-fluorouracil are 
frequently applied to the Tenon’s capsule during the procedure to combat this (Healey & Thomas, 
2010).  
II. 8 Other Surgical Options  
Silicon tube implants are an alternative to a trabeculectomy and allow the aqueous humor 
to drain into an external resevoir. These drainage devices are not as effective at lowering IOP, but 
carry fewer risks than incisional procedures (Weinreb et al., 2014). Congenital glaucoma, 
characterized by an abnormal iridocorneal angle, is most effectively treated by a combination of a 
trabeculotomy and a goniotomy, where the trabecular meshwork is cut from both the inside and 
outside of the eye (Healey & Thomas, 2010). The oldest surgical method for glaucoma treatment, 
the iridectomy, is indicated for patients who develop narrow-angle glaucoma as a result of a 
pupillary block (Dietlein et al., 2009).    
III. The Challenges of Managing Glaucoma 
 Proper management of glaucoma proves difficult for a variety of reasons, ranging from 
issues with patient adherence to the difficulties of designing an effective ocular drug delivery 
system. Compliance rates vary widely depending on the study, but the disease’s slow progression 
and the tedious medication regimen required to adequate manage the symptoms have convinced 
practitioners that there is a need for improvement (Hoevenaars, Schouten, van den Borne, Beckers, 
& Webers, 2008).   
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The human eye has several physiologic protective barriers, and has always posed a 
challenge to pharmaceutical scientists designing ocular drug delivery systems. Topical 
administration is the most common delivery route of glaucoma medications, but pre-corneal 
elimination and high tear fluid turnover reduce the bioavailability, and it is estimated that only 1-
5% of the active drug reach the target site of action (Achouri, Alhanout, Piccerelle, & Andrieu, 
2013). The low bioavailability of topical glaucoma drugs has led researchers to explore other 
ocular drug delivery systems, such as the solid lipid nanoparticle formulation designed in our 
project.  
 The low efficacy of topical glaucoma medications means that patients must frequently 
administer their eye drops to achieve desirable results, a factor that contributes to low adherence 
rates (Guadana, Jwala, Boddu, & Mitra, 2008). Studies have attempted to identify factors 
influencing drug persistency, which is defined as continuous therapy without more than a 90-day 
gap in treatment (Owen, Carey, de Wilde, Whincup, Wormald, & Cook, 2009). One study found 
no significant variability when analyzing gender and social factors, but did find that approximately 
one-third of all patients would fail to properly follow their medication regimens within the first 
year of treatment (Owen et al., 2009). Another study followed 10,260 subjects over a 12-month 
period and found that more than half stopped and restarted their medications, and only 10% 
followed their prescribed medication regimens continuously for the entire time period (Enhancing 
Adherence and Persistency in Glaucoma, 2008). 
 Additional studies have identified strong correlations between adherence rates and 
psychological factors, including motivation for treatment, intention to take medication, and the 
number of doses required in a given day (Cook, Schmiege, Mansberger, Kammer, Fitzgerald, & 
Kahook, 2015). Research into the psychometric properties determining medication adherence 
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found that white race, older age, and married marital status contributed to higher rates of 
persistency (Barker, Cook, Schmiege, Kahook, Kammer, & Mansberger, 2015). 
 Low bioavailability and adherence rates are not the only issues in glaucoma management. 
All current therapeutic options, whether pharmaceutical or surgical, exert their effect by lowering 
the intraocular pressure of the eye. However, vision impairments associated with glaucoma occur 
as a result of cellular and molecular changes that are detrimental to the retinal ganglion cells, nerve 
fiber layer, superior colliculi, lateral geniculate nuclei, and the visual cortex (Liu & Pang, 2013). 
These damages place glaucoma into the category of neurodegenerative disorders, and the need for 
a drug offering neuroprotection cannot be ignored.  
 In response to the need for a neuroprotective treatment option, memantine, currently FDA-
approved for the treatment of Alzheimer’s Disease, entered clinical trials as a potential therapy 
providing neuroprotection in glaucoma patients. Unfortunately, the drug failed in phase III trials, 
deterring optimism of finding a viable neuroprotective therapy for glaucoma (Baltmr, Duggan, 
Nizari, Salt, & Cordeiro, 2010).  However, recent advances in nanotechnology have provided 
researchers with an innovative way to design a drug delivery system capable of providing 
neuroprotection. Nanotechnology provides a way to deliver drugs to the anterior segment of the 
eye, where the detrimental neurologic damage takes place (Cholkar, Patel, Vadlapudi, & Mitra, 
2013). Research has indicated that nanotechnology can provide a delivery system capable of 
prompting retinal ganglion cell regeneration, thus providing neurological protection (Zarbin, 
Montemagno, Leary, & Ritch, 2013).  
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IV. Cannabinoids and Their Potential in Glaucoma Management  
 In 1971, a study conducted by Hepler and Frank reported a 25-30% reduction in IOP levels 
after smoking marijuana, sparking interest in utilizing cannabinoids in the treatment of glaucoma 
(Hepler & Frank, 1971). Documentation of the medicinal capabilities of marijuana date back to 
2737 BC, when the Chinese emperor Shen Nung wrote about its many medicinal purposes in a 
traditional Chinese medicine book (Tomida, Pertwee, & Azuara-Blanco, 2004). Marijuana was 
believed to treat a variety of ailments, including stomach pain, psychosis, chronic cough, and 
epilepsy, and was frequently prescribed by physicians until its removal from the United States 
pharmacopeia in 1942 (Tomida et al., 2004). Medicinal marijuana is currently legal in 23 states, 
carrying indications for treating multiple sclerosis symptoms, neuropathic pain, Tourette 
syndrome, insomnia, chemotherapy-induced nausea and vomiting, and cachexia associated with 
HIV infection (Metts, Wright, Sundaram, & Hashemi, 2016).  
 The cannabis plant itself contains more than 480 chemical constituents, but Δ9-
tetrahydrocannabinol has been identified as the active ingredient. The structure of Δ9-THC, seen 
in Figure 5, was first determined in the 1960s by Gaoni and Mechoulam.  
 
Structure of Δ9-tetrahydrocannabinol (Tomida et al., 2004) 
Figure 5 
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 Marijuana, along with other cannabinoids, have been found to exert their effects through 
action at cannabinoid receptors, which include two subtypes: CB1 and CB2,(Pertwee, 2006). CB1 
receptors are predominantly found at the nerve terminals of central and peripheral cells, although 
some are expressed in non-neuronal cells in the immune, reproductive, and endocrine systems. 
CB2 receptors are expressed primarily by immune cells (Tomida et al., 2004). In 1996, CB1 
receptors were discovered in the eye, and further research found them to be localized in the 
anterior chamber and on the retina (Straiker, Maguire, Mackie, Lindsey, 1999). These 
discoveries helped to explain the findings of Hepler and Frank’s study in 1971, and provided 
researchers with hope that these receptors could be selectively targeted as a treatment option for 
glaucoma (Straiker et al., 1999).  
IV. 1 The Classification of Cannabinoids 
 Although Δ9-tetrahydrocannabinol is the most studied cannabinoid, numerous other 
cannabinoids, both synthetic and naturally occurring, exist and have been used in exploring the 
ability of cannabinoids to treat glaucoma (Jarvinen, Pate, & Laine, 2002). Cannabinoids are 
generally classified into four different categories based on their chemical structures.  
Classical cannabinoids retain the natural cannabinoid ring structures with their oxygen 
atoms, as seen in Figure 6. Naturally occurring classical cannabinoids include Δ9-THC, 
cannabidiol, and cannabinol. Synthetic classical cannabinoids include synhexyl and nabilone. As 
a result of Hepler and Frank’s study, which utilized Δ9-THC, many studies of cannabinoids in 
humans and animals have been carried out using classical cannabinoids (Jarvinen et al., 2002).  
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Chemical structures of classical cannabinoids (Jarvinen et al., 2002) 
Figure 6 
 The second category of cannabinoids, the non-classical cannabinoids, are bicylic analogs 
of Δ9-THC that lack a pyran “B” ring. One member of this group, CP-55, 940, is commonly used 
in cannabinoid receptor-binding studies (Jarvinen et al., 2002). In regards to glaucoma, CP-55, 
940 was found to lower IOP in both normotensive rabbits and rabbits with elevated IOP levels 
(Sugrue et al., 1996). 
 Aminoalkylindoles form the third category of cannabinoids. The prototype molecule of 
this category is WIN 55, 212, which has been utilized widely in studies demonstrating the IOP 
lowering effects and is the molecule we used in our project. Although it targets the same 
receptors, WIN 55, 212 bears little resemblance to the chemical structure of classical 
cannabinoids, as seen in Figure 7.  
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Chemical structure of WIN 55, 212 (Hingorani, Gul, Elsohly, Repka, & Majumdar, 2012) 
Figure 7 
 The final category, the endocannabinoids, are molecules produced within the body that 
naturally activate cannabinoid receptors. Numerous endocannabinoids have been identified, 
including arachidonylethanolamid, bimatoprost, and HU-211 (Jarvinen et al., 2002).  
IV. 2 The Neuroprotective Capabilities of Cannabinoids 
 The ability of cannabinoids to lower IOP triggered initial research into their use as 
glaucoma treatments, and recent discovery that cannabinoids may offer neuroprotection has 
fueled researchers to conduct further studies (Yazulla, 2008). Research has found that 
cannabinoids may offer protection against traumatic, ischemic, inflammatory, and neurotoxic 
damage in the central nervous system (Yazulla, 2008). The vision loss that occurs in glaucoma 
results from ischemia of the retinal ganglion cells. Ischemia triggers excessive aspartate and 
glutamate release, which subsequently activates NMDA receptors, the first step in the apoptotic 
pathway that leads to cell death (Yazulla, 2008). A study done by Shen and Thayer showed that 
administration of a synthetic cannabinoid in rats inhibited hippocampal neurons from releasing 
glutamate (Shen & Thayer, 1999). Research conducted on the retinas of cattle concluded that 
cannabinoids exerted inhibitory action on both potassium and ischemia induced release of 
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aspartate through the action of CB1 receptors (Opere, Zheng, Zhao, Lee, Kulkarni, & Ohia, 
2006). These findings have lead researchers to believe that in addition to lowering IOP, 
cannabinoids also offer something that no other glaucoma drug can: neuroprotection.  
V. Designing a Viable Ocular Drug Delivery System for Cannabinoids  
 Following the publication of Hepler and Frank’s study discussing the effectiveness of 
marijuana cigarettes in lowering IOP, several additional studies were conducted in the 1970s and 
1980s utilizing different delivery methods. By the end of the 1908s, publications had shown the 
ability of Δ9-THC to lower IOP when delivered intravenously, orally, or through inhalation 
(Porcella, Maxia, Gessa, & Pani, 2001). The systemic effects resulting from these delivery 
methods discouraged many from thinking that Δ9-THC could serve as a viable glaucoma 
treatment option, but the discovery of localized cannabinoid receptors in the eye left researchers 
hopeful for a targeted drug delivery system (Straiker et al., 1999).  
Following the discovery of cannabinoid receptors in the eye, researchers became interested 
in the local effects of CB1 agonists. Researchers found that activating CB1 receptors in the ciliary 
muscle induced its contraction, subsequently widening the intercellular spaces of the trabecular 
meshwork and increasing the outflow of aqueous humor, a process that results in lower IOP levels 
(Llobet, Gasull, & Gual, 2003). One of the first published studies on the effectiveness of topical 
administration utilized 0.05% Δ9-THC in mineral oil and reported a 4.8 mm drop in IOP without 
a subsequent drop in systemic blood pressure, indicating that Δ9-THC was acting on local receptors 
in the eye (Merritt, Olsen, Armstrong, & McKinnon, 1981). Δ9-THC is a highly lipophilic 
molecule, which hinders its permeability across the cornea when delivered topically, explaining 
why early studies of topical administration did not show significant drops in IOP (Hingorani, Gul, 
ElSohly, Repka, & Majumdar, 2011). Significant increases in the concentration of Δ9-THC in 
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topical formulations successfully reduced IOP, but resulted in systemic effects, highlighting the 
need for a formulation that would successfully deliver the molecule through the cornea without 
dramatically increasing the concentration (Hingorani et al., 2011).  
Successfully formulating topical Δ9-THC drug delivery systems is challenging for a variety 
of reasons, most notably because of its poor solubility in aqueous media and its susceptibility to 
oxidation, hydrolysis, thermal, and photolytic degradation. To enhance the delivery of Δ9-THC, 
researchers have focused on formulating complex prodrugs. One method is to modify the solution 
that the active drug ingredient is in. Cyclodextrins are molecules with hydrophilic surfaces and 
hydrophobic cores, and are widely used in formulations of poorly soluble drugs to enhance their 
solubility, bioavailability, and stability profiles (Gaurav, Tiwari, & Rai, 2010). 2-Hydroxypropyl-
β-cyclodextrin (HPβCD) is one of the most commonly used cyclodextrins, and has been shown to 
be safe and well tolerated when topically administered to the eye (Loftsson & Stefansson, 1997). 
Δ9-THC in 2.5% HPβCD solutions with Dulbecco’s phosphate-buffered saline (DPBS) had a 
permeability 300 times that of Δ9-THC in light mineral oil-based formulations, which had been 
the most common drug delivery vehicle used in early studies (Hingorani et al., 2011). In the same 
study, prodrugs of Δ9-THC were synthesized to form hemisuccinate (THC-HS) and hemiglutarate 
(THC-HG) esters, seen in Figure 8. Researchers found that the ester prodrugs, in combination with 
a buffered solution and prodrug-ion-pair complexes formed using L-arginine or tromethamine, 
resulted in significant improvements of permeability (Hingorani et al., 2011). Although in vitro 
results from this study showed that the use of an ion-pair complex of THC-HG could be an 
effective strategy for topical delivery of THC, our research focused on other prodrug formulations 
to further enhance the ocular delivery and bioavailability.  
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Chemical structures of THC-HS and THC-HG (Hingorani et al., 2011)  
Figure 8 
Solid lipid nanoparticles (SLNs) were first patented by Muller and Lucks in 1996, and are 
a type of nanotechnology delivery system that is capable of accommodating drugs with poor 
physiochemical properties by increasing their solubility (Seyfoddin, Shaw, & Al-Kassas, 2010). 
It has been documented that SLNs are capable of enhancing the corneal permeability of drugs, 
leading to an increase in the drug’s uptake by the ocular tissues and bioavailability (Seyfoddin & 
Al-Kassas, 2013). The aim of this study was to create an SLN formulation that would enhance 
the corneal permeability and bioavailability of the synthetic cannabinoid WIN 55, 212. First, a 
formulation with favorable physiochemical characteristics was made, then the formulation was 
subjected to both in vitro and in vivo studies to measure the viability of the drug delivery system 
as a treatment option for the management of glaucoma. 
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Materials and Methods 
I. Materials 
 In the formulation of the SLN, the aqueous phase contained Poloxamer 188, Tween 80, 
and glycerin were used. The lipid phase contained WIN 55, 212 and Compritol® 888 ATO 
(glyceryl behenate). The phases were combined to form a premix and then subjected to 
emulsification using the T 25 digital Ulta-Turrax (IKA® Works, Inc.). The control formulation 
was prepared using WIN 55, 212 and Tocrisolve™. After the formulation had been made, its 
particle size and poly dispersity index were determined by photon correlation spectroscopy using 
Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc.). The entrapment efficiency and assay 
were determined after dilution with 190-proof alcohol using an HPLC system.  
To test the in vitro transcorneal permeability, a Franz diffusion apparatus (PermeGear, Inc., 
Hellertown, PA) was used with Spectra/Por® membranes (molecular weight: 10,000 Daltons). The 
results of the in vitro studies were analyzed using the HPLC-UV method utilizing a Phenomenex® 
Luna® C18(2) HPLC column and acetonitrile and trifluoroacetic acid for the mobile phase. For 
the in vivo studies, glaucoma was induced in male albino New Zealand rabbits by injecting alpha-
chymotrypsin intravitreally. After administering the SLNs, IOP levels were measured using a 
TONO-PEN® vet tonometer. The rabbits were subsequently euthanized with a dose of 
phenobarbital, and their eyes were enucleated and sent to Excalibur Pathology Inc. for corneal 
histology testing to be done.  
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II. 1 Experimental Methods - Designing a Solid Lipid Nanoparticle Formulation of WIN 55, 212 
with Appropriate Physiochemical Properties 
 Formulating WIN-SLNs utilizes the hot homogenization method and begins by preparing 
the aqueous phase. The aqueous phase contains two surfactants: 0.25% w/v Poloxamer 188 and 
0.75% w/v Tween 80. In addition, the aqueous phase contains 2.25% w/v Glycerin. To prepare the 
lipid phase, 4% w/v of the lipid excipient Compritol 888 ATO was melted followed by the addition 
of 0.4% w/v of WIN 55, 212. During the preparation of the lipid phase, the aqueous phase was 
heated and added to the melted lipid phase in a beaker being magnetically stirred at a speed of 600 
rpm. The two phases were stirred for a total of two minutes to form the premix. The premix was 
then emulsified using the T 25 digital Ultra-Turrax (IKA® Works, Inc.) dispersion homogenizer. 
The premix was subjected to emulsification for 5 minutes at a speed of 16,000 rpm, forming the 
heated pre-emulsion. The pre-emulsion was then subjected to high-pressure homogenization using 
the EmulsiFlex-C5 (Avestin) homogenization using a pulse of 15 seconds and amplitude of 80% 
for a total of 5 minutes. The temperature throughout the entire homogenization process was held 
constant at 80°C ± 2°C. After the 5-minute homogenization period was complete, the emulsion 
was allowed to slowly cool to room temperature to form the WIN-SLN formulation. After the 
preparation of the SLN complete, several physiochemical characteristics were assessed to ensure 
the efficacy of the formulation. The characteristics measured were particle size, polydispersity 
index, zeta potential, entrapment efficiency, and assay. 
To assess the average particle size of the formulation, photon correlation spectroscopy 
technology was employed by using the Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc.).  
Backscatter detection at 25°C and 173°C was utilized in disposable folded capillary clear cells and 
the measurements were obtained using a He-Ne laser of 633 nm. This same technology was also 
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employed to determine the polydispersity index (PDI) of the SLN. The PDI is indicative of the 
degree of “non-uniformity” of a sample. To assure stability, uniformity of SLNs is desired. Zeta-
potential, a measurement of the magnitude of the electrostatic repulsion or attraction between 
particles, was assessed using the same instrument and was carried out at a temperature of 25°C in 
folded capillary cells. Zeta-potential measurements are frequently taken when assessing the 
stability of nanoparticles with any measurement between -10 and +10 mV indicating neutrality 
and any measurement greater than +30 mV or less than -30 mV indicating strong cationic or 
anionic properties. Cellular membranes are typically anionic, and a strong cationic zeta potential 
may pose a threat to cell membrane integrity, making this property an important consideration in 
formulations.  
Entrapment efficiency of the SLN formulation was the next parameter analyzed. The 
entrapment efficiency is the percentage of drug encapsulated within the solid lipid nanoparticle 
core. The percentage of free drug in solution should be kept to a minimum to assure that the 
formulation is stable and that bioavailability will be high. To measure the entrapment efficiency 
(EE) of the SLN, the lipid was precipitated using 190-proof alcohol, and the drug content in the 
supernatant after 20 minutes of centrifugation at 13,000 rpm was measured using the HPLC-UV 
method. To measure the concentration of free drug in the aqueous phase of the WIN-SLN 
formulation, an ultrafiltration technique was employed using a 100-kDa centrifugal filter device 
composed of a regenerated cellulose membrane (Amicon Ultra). An aliquot containing 500 mL of 
the undiluted WIN-SLN was added to the sample reservoir and centrifuged for 10 minutes at 5,000 
rpm. The filtrate obtained was further diluted with 190-proof alcohol, and then analyzed for drug 
content using the HPLC-UV method. The entrapment efficiency was then estimated based on an 
equation that considers the total drug content and the amount of free drug in the aqueous phase.  
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II. 2 Testing the Solid Lipid Nanoparticle Formulation in vitro by Conducting Permeability and 
Release Studies 
After formulating a WIN-SLN with desirable physiochemical characteristics, the drug’s 
efficacy was determined by conducting in vitro permeability and drug release studies. Before 
conducting these studies, a control formulation was prepared. To prepare the control, an accurately 
weighed amount of WIN 55, 212 was combined with Tocrisolve™ to give a 0.4% w/v WIN 55, 
212 control formulation. The combined mixture of the drug and Tocrisolve™ emulsion was 
subjected to sonication for 10 minutes, and the drug content was evaluated using the HPLC-UV 
method. When analyzing the control formulation, a Phenomenex® Luna® C18(2) column was 
used. The mobile phase contained a 50:50 solution of acetonitrile/water + 0.5% trifluoroacetic 
acid. The flow rate was 1 mL/min, the injection volume was 25 μL, and the UV wavelength was 
set at 315 nm. 
After successfully preparing the Tocrisolve™ control formulation, the in vitro release and 
permeability studies were conducted using a Franz diffusion apparatus (PermeGear, Inc., 
Hellertown, PA). The Franz diffusion apparatus is comprised of an entry for the donor compound, 
a receptor chamber containing a stir bar, and a sampling port as seen in Figure 9.  
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Structure of a Franz diffusion apparatus 
Figure 9 
The two in vitro studies differed only in which membrane was used – the drug release 
study used the synthetic Spectra/Por® membrane and the permeability studies used corneas 
excised from whole New Zealand rabbit eye globes. Both in vitro studies began by adding 100 
μL of the 0.4% w/v WIN-SLN to the donor portal of one apparatus and 100 μL of the 0.4% w/v 
Tocrisolve™ control formulation was added to the entry portal of the other apparatus. The 
receiving chambers of both contained 5 mL of 5% w/v of Randomly Methylated β-Cyclodextrin 
(RMβCD) in isotonic phosphate buffer saline (IPBS) having a pH of 7.4. Both studies took place 
over a duration of 3 hours, and samples were collected at 30 minute intervals. After each sample 
of 0.6 mL had been taken from the sampling port, 0.6 mL of the IPBS buffer were subsequently 
added to keep the total volume in the receiving chamber constant. After both studies were 
complete, the collected samples were then analyzed using the HPLC-UV method.   
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Analysis of the samples was done under the same conditions as the control formulation 
using a Phenomenex® Luna® C18(2) column and a mobile phase of 50:50 acetonitrile/water + 
0.5% trifluoroacetic acid with a flow rate of 1 mL/min and an injection volume of 25 μL. As 
with the analyzation of the control formulation, the UV wavelength was set at 315 nm. 
The in vitro permeability studies were then carried out to further assess the bioavailability 
of the drug. Whole rabbit eye globes were obtained and the corneas were enucleated to be used as 
the membrane in the Franz diffusion apparatus. As in the drug release study, 100 μL of both 
formulations was added to the entry portal and the receiving chambers contained 5 mL of RMβCD 
in IPBS having a pH of 7.4. This study also had a duration of 3 hours, with samples being collected 
every 30 minutes. The samples for this study were assessed on three parameters: rate, flux, and 
permeability.  
III. 3 Testing the Pharmacodynamic Response in vivo  
After formulating a WIN 55, 212 SLN with appropriate physiochemical characteristics 
and carrying out the initial in vitro studies, the in vivo studies were initiated. The animal model 
chosen for the in vivo studies were male albino New Zealand rabbits, primarily because of the 
size of their eye globes and docile nature. Male New Zealand albino rabbits (2-2.5 kg) procured 
from Harlan Laboratories® (Indianapolis, IN) were used in all the studies. All animal 
experiments conformed to the tenets of the Association for Research in Vision and 
Ophthalmology statement on the Use of Animals in Ophthalmic and Vision Research and 
followed the University of Mississippi Institutional Animal Care and Use committee approved 
protocols. 
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The in vivo experiments were carried out in two separate phases. The first phase analyzed the effect 
of the Tocrisolve™ control formulation on IOP levels of two of the rabbits involved in the study. 
Prior to testing the formulation, glaucoma was induced in the right eye of each rabbit by 
administering an intravitreal injection of 50 μL of 20 mg/mL of α-chymotrypsin. The enzyme α-
chymotrypsin results in increased IOP levels, the phenomenon that ultimately leads to the 
pathophysiology of glaucoma. After the intravitreal injections were administered, the study 
population was closely monitored for any sign of infection or inflammation the IOP levels were 
allowed to stabilize over a two-week time period.   
 After the two-week stabilization period, the basal IOP readings of each rabbit were taken 
prior to the administration of the control formulation using the TONO-PEN®. After the basal IOP 
values were established, the WIN 55, 212 Tocrisolve™ formulation was topically administered to 
the right eye of both rabbits involved in the study. A total of 50 μL of 0.4% w/v control formulation 
was administered to each eye. Each dose contained 0.2 mg of WIN 55, 212. The study took place 
over a 120-minute duration, and IOP readings were taken at 30-minute time intervals to determine 
when the maximum IOP reductions took place.  
 After the completion of the first phase of the in vivo study, the remaining three rabbits of 
the study population were given instillations of the WIN-SLN formulations. Glaucoma was 
induced in the same fashion as in the first phase, by administering an intravitreal injection of 50 
μL of 20 mg/mL of α-chymotrypsin two the right eye, followed by a two-week time period for 
stabilization of IOP levels. After the IOP levels had stabilized, basal IOP levels were recorded 
before administering the SLN formulations.  
After the baseline IOP readings were recorded, 50 μL of the 0.4% w/v WIN-SLN 
formulation was topically administered to the right eyes of the three rabbits involved in the 
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study. Each instillation contained a 0.2 mg dose of WIN 55, 212. The duration of the study was 
dependent on the IOP readings taken at each 30-minute time interval, and the study was 
terminated when the IOP levels of the glaucomatous eyes had returned to 90% of the baseline 
IOP reading. The study had a duration of 180 minutes and IOP readings were recorded every 30 
minutes. 
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Results and Discussion:  
 Prior to initiation of the in vitro and in vivo testing, a solid lipid nanoparticle formulation 
was prepared with favorable physiochemical properties. Several solid lipid nanoparticle 
formulations were prepared, but the 0.4% w/v formulation had characteristics that most aligned 
with the goals of the remaining in vitro and in vivo testing of the study. The results of the 
physiochemical property testing are shown below in Table 1. A favorable particle size for SLN 
formulations ranges from 200-500 nm. A particle size below 200 nm carries with it the risk of 
being washed away in the blood, and a particle size exceeding 500 nm will not successfully 
permeate the ocular tissues. Poly dispersity index is used as a measure of the uniformity of the 
particles in the formulation. A range of 0.2-0.4 is acceptable for SLN formulations. Zeta potential 
represents a way to estimate the formulation’s stability, and any value exceeding 20 mV is 
considered stable. Although an entrapment efficiency exceeding 80% is desired, our formulation’s 
entrapment efficiency was deemed acceptable because it had optimal physiochemical 
characteristics otherwise.  
Characteristics 0.4% w/v SLN 
Particle size (nm) 372 ± 21 nm 
Poly dispersity index (PDI) 0.24 ± 0.04 
Zeta potential (mV)  21.0 mV 
Entrapment efficiency 72.6%  
Assay 100-106% 
 
Results of WIN 55, 212 SLN physiochemical testing 
Table 1 
41 
 
 
After the SLN formulation’s physiochemical characteristics had been analyzed and 
deemed favorable, the in vitro drug release and permeability studies were carried out. The release 
study was conducted over three hours, and the samples in the donor chamber of the diffusion 
apparatus were analyzed to determine the percentage of drug crossing the membrane. The 
results, seen in Table 2, show that the SLN allowed a higher concentration of WIN 55, 212 to 
cross the membrane when compared to the control.  
Formulation % of Total WIN 55, 212 Crossing the Membrane 
0.4% w/v Tocrisolve™ Control Formulation 21.3 ± 1.7% 
0.4% w/v WIN-SLN Formulation 29.1 ± 3.1% 
 
Results of in vitro drug release studies 
Table 2 
The in vitro permeability studies were then completed to further estimate the WIN SLNs 
bioavailability in vivo. Samples were analyzed using the HPLC-UV method on three different 
parameters: rate (μg/min), flux (μg/min/cm2), and permeability x 106 (cm/sec). The rate simply 
quantifies the amount of WIN 55, 212, in μg, that was able to pass through the rabbit cornea 
membrane each minute over the duration of the study. The rate of the Tocrisolve™ control 
formulation was found to be 0.063 μg/min, while the WIN-SLN had a membrane crossing rate of 
0.13 μg/min. The next parameter analyzed was flux. The WIN-SLN was analyzed to have a flux 
of 0.2 μg/min/cm2, twice that of the 0.1 flux value of the Tocrisolve™ control formulation. The 
final parameter analyzed was the permeability. The WIN-SLN had a permeability of 0.84 x 106 
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cm/sec, while the Tocrisolve™ emulsion had a permeability of 0.41 x 106 cm/sec. The results, 
seen in Figure 10, show the SLN as being twice as permeable when compared to the control 
formulation based on rate, flux, and permeability.  
 
Results of in vitro permeability study 
Figure 10 
The 0.4% w/v WIN SLNs continued to show favorable experimental results, leading to 
the initiation of the in vivo testing of the formulation in an animal model. The in vivo testing was 
the final component to this study. After the rabbits were induced with glaucoma and their IOP 
levels stabilized, basal IOP levels were recorded using the TONO-PEN® prior to the 
administration of the control formulation. Each rabbit eye was subjected to a total of three 
readings, and the average of the three was recorded, as seen in Table 3.  
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Rabbit No   Basal 
    1 2 3 Avg 
87 Right (G) 21 21 19 20.3 
  Left (N) 20 19 18 19.0 
            
91 Right (G) 19 20 21 20.0 
  Left (N) 19 19 20 19.3 
  
Results of basal IOP readings 
Table 3 
After the basal IOP readings were recorded, both animals received instillations of the 
control formulation in the right eye. A total of 50 μL of 0.4% w/v control formulation was 
administered, with each dose containing 0.2 mg of WIN 55, 212. The study took place over a 
120-minute duration, and IOP readings were taken at 30-minute time intervals. A total of three 
readings were taken of the right eye at each interval, and the average of the three was recorded, 
shown in Table 4.  
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Time Interval 
Average IOP Reading (mmHg) of Rabbit 
Number: 87 
Average IOP Reading 
(mmHg) of Rabbit 
Number: 91 
30 minutes 12.7 13.7 
 60 minutes 15.0 17.7 
90 minutes 17.7 20.0 
120 minutes 22.3 24.0 
 
Results of IOP readings after installation of control formulation 
Table 4 
After the study was complete, the IOP levels were recorded as a function of the percent 
of baseline IOP. This allows the determination of when the maximum IOP reduction was for 
each animal. Both animals saw a maximum IOP reduction at the 30-minute time interval. Rabbit 
87 experienced a 37.6% maximum IOP reduction rabbit 91 experienced a 29.2% maximum IOP 
reduction, shown in Table 5.  
    
% Change from 
Baseline 
30 
mins 
60 
mins 
90 
mins 
120 
mins 
Rabbit Number            
87 Right 100.0 62.4 73.9 87.0 110.0 
  Left 100.0         
91 Right 100.0 70.8 91.5 103.6 124.4 
  Left 100.0         
 
% Change in IOP from baseline with control formulation 
Table 5 
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After the control formulations had been tested and the results were quantified, the three 
remaining rabbits in the study population were given instillations of the WIN SLN formulations. 
As with the control formulations, the basal IOP readings were taken after a two-week 
stabilization period. The results can be seen in Table 6.  
Rabbit No   Basal IOP Reading  
    1 2 3 Average 
85 Right (G) 27 29 30 28.7 
  Left (N) 16 14 17 15.7 
            
88 Right (G) 26 26 27 26.3 
  Left (N) 16 15 17 16.0 
      
89 Right (G) 35 36 33 34.7 
 Left (N) 19 20 19 19.3 
 
Results of basal IOP readings of rabbits receiving WIN-SLN 
Table 6 
 After the baseline IOP levels were recorded, each rabbit received 50 μL of the 0.4% w/v 
WIN-SLN formulation containing a total of 0.2 mg of WIN 55, 212. The study was terminated 
when the IOP levels of the glaucomatous eyes had reached 90% of the baseline IOP levels, 
which was 180 minutes. The IOP readings were taken every 30 minutes. The results can be seen 
in Table 7.  
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Time Interval 
Average IOP Reading 
(mmHg) of Rabbit 
Number 85 
Average IOP Reading 
(mmHg) of Rabbit 
Number 88 
Average IOP Reading 
(mmHg) of Rabbit 
Number 89 
30 minutes 22.0 21.7 26.3 
60 minutes 21.0 16.0 26.0 
90 minutes 21.0 17.3 22.7 
120 minutes 20.3 18.7 29.3 
150 minutes 27.7 24.3 29.7 
180 minutes 29.0 26.7 33.0 
 
Results of IOP readings after instillation of WIN-SLN 
Table 7 
 The results of the WIN-SLN and control formulation studies were then compared to 
determine the effectiveness of the solid lipid nanoparticle. The duration of effect of the 0.4% w/v 
WIN-SLN formulation was found to be four times that of the control formulation, which can be 
seen in Figure 11.  
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Effectiveness of control formulation versus WIN-SLN 
Figure 11 
Immediately following the conclusion of the WIN 55, 212 SLN study, the rabbits were 
euthanized by a lethal dose of pentobarbital. given through the marginal ear vein. After being 
euthanized, the right eye of each rabbit was enucleated and washed. The ocular tissues were then 
separated, weighed, and preserved at -80°C until they were shipped to Excalibur Pathology to 
assess them for any damages or changes when compared a control. The corneal cross-sections 
were stained with hematoxylin-eosin. The top cross-sections were the controls that were exposed 
to phosphate-buffered saline. The bottom cross-sections were the corneas exposed to the SLN 
formulation. The results show that corneas exposed to the SLN did not have any significant 
changes when compared to the control. Figure 12 shows the results of the histology testing, with 
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(1) representing the control corneas that were exposed to a phosphate-buffered saline and (2) 
showing the corneas exposed to the SLN formulation. 
 
Results of the histology testing 
Figure 12 
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Conclusion 
 When used correctly, current marketed glaucoma treatments have proven effective in 
lowering intraocular pressure levels. However, the search continues for a drug that could 
successfully provide an increased duration of action and protection of the optic nerve. Topically 
administered eye drops for glaucoma are not able to permeate the posterior segment where the 
optic nerves are found, and are confined to the anterior segment where they exert their action by 
modifying aqueous humor production and outflow. Drug delivery systems utilizing 
nanotechnology have been speculated as a viable option to provide what other glaucoma drugs 
cannot, the ability to reach the posterior segment and to sustain a drug’s length of action. Solid 
lipid nanoparticles serve as a vehicle for drugs with poor physiochemical properties, and we 
explored the effectiveness of these formulation systems in our research.  
 After the preparation of the solid lipid nanoparticle is complete, we had to confirm that 
the formulation possessed favorable physiochemical characteristics that would allow it to be 
successful in subsequent in vitro and in vivo studies. Our WIN 55, 212 SLN showed favorable 
physiochemical characteristics, prompting us to move forward with the in vitro studies. When 
compared to the control formulation, the WIN 55, 212 SLN showed a two-fold increase in rate, 
flux, and transpermeability. These results confirm the solid lipid nanoparticle delivery systems 
ability to enhance the permeability of the drug, and is indicative that higher bioavailability will 
be found during in vivo studies.  
 When tested in vivo, the WIN 55, 212 SLN formulation sustained a drop in intraocular 
pressure that was four times as long as the control formulation. These results confirm the solid 
lipid nanoparticle’s ability to extend the duration of action of WIN 55, 212. The results of this 
project provide evidence that solid lipid nanoparticles are a drug delivery system that can provide 
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increased bioavailability and can lengthen the duration of action. This delivery system was able 
to effectively deliver the cannabinoid WIN 55, 212 into the ocular tissues, and it can be 
extrapolated that other topically administered ocular drugs may benefit from this delivery system 
or other forms of nanotechnology.  
 Overall, the WIN 55, 212 formulation exhibited desirable physiochemical characteristics 
and was successful in the in vitro and in vivo studies. Although the SLN formulation extended 
WIN 55 212’s ability to lower intraocular pressure, it did not outlast Pilocarpine eye drops, one 
of the many glaucoma treatments available on the market. Further studies are required to 
optimize the SLN formulation to increase its efficacy when compared to current FDA marketed 
glaucoma drugs.  
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